Figure 2.
Sitagliptin improves NODAT control and is associated with a decline in BMI but no effect on serum lipids. (a) Diabetes control as measured by hemoglobin A1c for the entire cohort (n = 22) at 6 and 12 months after initiation of sitagliptin. (b) BMI for the entire cohort (n = 22) at start of sitagliptin compared to 12-month followup. (c), (d) Serum LDL-cholesterol and HDL-cholesterol at start of sitagliptin compared to 12-month followup. Data shown as mean + SD. **P < 0.01, *P < 0.05.